Investors who bought Immutep Limited stock between March 24, 2025 and March 12, 2026 now face a tight deadline. July 6, 2026 is the cutoff date to contact the Schall Law Firm about joining a class action lawsuit. The lawsuit centers on the company’s TACTI-004 trial for eftilagimod alfa.
That trial, according to the complaint, failed to meet its primary efficacy endpoints. But investors allege Immutep kept that failure hidden.
The Schall Law Firm, a national shareholder rights litigation firm based in Los Angeles, is leading the charge. The firm specifically reminds investors that the lawsuit alleges violations of sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Those are the core federal securities fraud provisions.
Here is the crux of the allegation. On January 30, 2026, Immutep filed a Form-K with the SEC.
In that filing, the company claimed to be demonstrating “strong operational progress.” The lawsuit alleges that at that very moment, the company knew the TACTI-004 trial was going to fail. If true, those public statements were false and materially misleading. The class period spans roughly one year.
Anyone who purchased Immutep securities during that window and suffered a loss is eligible to participate. The class has not yet been certified. That means no attorney currently represents the group.
Investors who do nothing can remain absent class members. What is at stake is straightforward.
Investors who bought stock based on what they thought were accurate statements about a key drug trial lost money when the truth came out. The trial was not a minor piece of the company’s pipeline. Eftilagimod alfa was a central product candidate.
A failed trial directly affects the company’s valuation and future prospects. For investors, the choice is binary.
Contact the Schall Law Firm before July 6 and potentially join the lawsuit. Or do nothing and watch from the sidelines as the case proceeds. The Schall Law Firm can be reached at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067.
The phone number is 310-301-3335. The firm says discussions about investor rights are free of charge. This is not a case where the company simply missed its own targets.
The accusation is that Immutep knew the trial was failing and told the market otherwise. That distinction matters for the legal claim.
A failed trial is business risk. Concealing that failure while selling stock to the public is fraud, if the allegations hold up. The SEC filing on January 30, 2026 is the key document.
It was the company’s official statement to regulators and the market. If the lawsuit is correct, that filing contained false assurances at a time when the company’s internal data told a different story.
Investors who bought after that filing and before March 12, 2026 are the ones most directly affected. They bought into a narrative that the company now allegedly knew was false. The stock price drop when the trial results became public is the damage.
The Schall Law Firm specializes in these cases. They are a national firm handling shareholder rights litigation. The Los Angeles address and phone number are the contact points for investors seeking information.
No court has yet certified the class. That is a procedural step that will come later.
For now, the deadline is the immediate concern. July 6 is less than two weeks from the June 22 announcement. Investors who want to participate need to act.
The firm is actively gathering names and information from those who bought Immutep securities during the class period. The free consultation offer is standard practice in these cases.
The complaint itself lays out the timeline and the specific allegations. The company’s concealment of the TACTI-004 trial results, according to the complaint, had significant implications for investors. Those implications are now playing out in court.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Immutep Faces Class Action Over Allegedly Hidden TACTI-004 Trial Failure”, “description”: “Investors who bought Immutep Limited stock between March 24, 2025 and March 12, 2026 now face a tight deadline. July 6, 2026 is the cutoff…”, “datePublished”: “2026-06-22T08:02:00+00:00T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Ava Anderson”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
